Tag: Pomalidomide

Pomalidomide may become the first approved therapy for hereditary haemorrhagic telangiectasia

Presented By
Prof. Keith McCrae, Cleveland Clinic, OH, USA
Trial
Phase 2, PATH-HHT
Conference
ASH 2023
Type
Peer-reviewed article

7 February 2024 14:54

Oral selinexor/pomalidomide/dexamethasone shows activity in heavily pre-treated multiple myeloma

Presented By
Dr Christine Chen, Princess Margaret Cancer Centre, University of Toronto, Canada
Trial
MM-003, STOMP
Conference
ASH 2019
Type
Peer-reviewed article

5 March 2020 22:59

Adding isatuximab to pomalidomide and dexamethasone improves PFS and ORR in RRMM

Presented By
Prof. Michel Attal, University Institute Cancer Toulouse Oncopole, France
Trial
Phase 3, ICARIA-MM
Conference
EHA 2019
Type
Peer-reviewed article

9 August 2019 20:38

Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma

Presented By
Dr Paul G. Richardson, Dana-Farber Cancer Institute/Harvard Medical School, USA
Trial
Phase 2, ICARIA-MM
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 13:53
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com